2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1593

Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1566

HER2 as a Biomarker of Proliferative Lupus Nephritis in Children

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1104

Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1420

Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1378

High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1594

High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1568

High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1381

High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1154

Hispanic Patients with Rheumatoid Arthritis Have Greater Discordance Between Patient and Physician Global Estimates Than Other Ethnic Groups, Explained Largely by Fibromyalgia (FM) According to a FM Assessment Screening Tool 3 (FAST3)

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1655

Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1451

Histological Characteristics in SICCA Syndrome – Clinical and Serological Association

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1706

HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1605

Homocysteinemia Predicts Renal Insufficiency in Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1671

Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1186

How Accurate Is Physical Joint Inflammation of the MTP-joints and What Can We Learn from Additional MRI on Forefoot Involvement in Early Arthritis?

Imaging Of Rheumatic Diseases Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].